MedTrace Logo

Follow-up Measurement of Brain PDE10A Enzyme Levels in Huntington´s Disease Gene Expansion Carriers

NCT02956148 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2019-10-10

No results posted yet for this study

Summary

The aim of this study is to measure longitudinally the availability of the PDE10A enzyme in HDGECs using the radioligand \[18F\]MNI-659. The study will be a follow-up, examining HDGECs from the CHDIKI1201/PET-HD-PDE10A (NCT02061722) study from 18 to 28 months after the initial PET measurement.

Conditions

Interventions

RADIATION

Radioligand [18F]MNI-659

The effective radiation dose for the injection of \[18F\]MNI-659 is approximately 5.6 mSv (approximately 2 years of background radiation in Sweden) for an average person weighing 70 kg.

Sponsors & Collaborators

  • CHDI Foundation, Inc.

    lead OTHER

Principal Investigators

  • Andrea Varrone, MD, PhD · Karolinska University Hospital

  • Cristina Sampaio, MD, PhD · CHDI Foundation, Inc.

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
73 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-09-06
Primary Completion
2017-10-05
Completion
2017-10-05

Countries

  • Denmark
  • Netherlands
  • Norway
  • Sweden

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02956148 on ClinicalTrials.gov